It’s
quite a catching opener, especially if you’re an investor with an interest in
the biotech sector. It’s also a bold statement, though one backed by weighty
evidence. In an article published today, Wall Street Cheat Sheet contributor
James Ratz begins with:
“The
biggest story this week in biotechnology has been the explosion seen in shares
of CytRx Corporation (NASDAQ:CYTR). In fact, the recent move catapults CytRx to
one of the top performing biotechnology stocks of 2013, and what’s really
interesting is that based on the recent news, CytRx may be on the verge of
altering the cancer landscape …”
Comparing
CytRx’ rally to a previous one stunted by Pharmacyclics (PCYC), Ratz combs
through the reasons both companies’ ability to apply treatment to several diseases.
To
read the full article visit:
http://wallstcheatsheet.com/stocks/is-cytrx-corporation-the-next-pharmacyclics.html
CytRx
is developing aldoxorubicin as a potential alternative to the commonly used
chemotherapeutic agent doxorubicin. Aldoxorubicin’s primary application is for
soft tissue sarcoma, followed by a variety of other cancers including
glioblastoma multiforme and Kaposi’s sarcoma.
The
company recently released the results of its ongoing phase 2b clinical trial in
which aldoxorubicin met primary and secondary endpoints, boasting 80-100
percent superiority over doxorubicin in progression-free survival (PFS).
Adding
to the obvious potential of these results, Ratz suggests that CytRx could be
the “next Pharmacyclics” for three primary reasons:
• Platform applicable to multiple
diseases
• “Smart Money” purchasing shares
• Sudden share price explosion
The
article summarizes Pharmacyclics’ developments and its stock’s tremendous bull
run started in 2011, as well as provides supporting evidence for Ratz’s
assessment before concluding that:
“The
similarities between CytRx and Pharmacyclics are hard to ignore. A world class
platform that has the potential to cure millions and generate billions, a
significant institutional interest, and a rapid share price explosion, all lend
credence to the theory that CytRx may soon follow a similar path to
Pharmacyclics. Dr. Gene Salkind and the other institutions on board are likely
adding to their already massive holdings as I write this article, hoping that
this run is just getting started.”
For
more information visit www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
